Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Barbara Pistilli, MD, discusses the mechanism of action of novel ADCs, the ways in which ADC targets in breast cancer can change over time, and how future research may pave the way for individualized treatment with this class of agents.
Auron Establishes Premier Scientific Advisory Board to Support the Advancement of its AI-Powered Platform and Pipeline Targeting Cellular Plasticity in Cancer tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
CHICAGO — Ivosidenib extended median OS more than three times longer than placebo when added to azacitidine for adults with treatment-naive, IDH1-mutated acute myeloid leukemia, according to updated results of the phase 3 AGILE trial.The long-term follow-up data, presented at ASCO Annual Meeting, showed an additional 5-month increase in median OS with the ivosidenib (Tibsovo, Servier)
A single dose of patritumab deruxtecan provoked a response in nearly one third of patients with HR-positive/HER2-negative or triple-negative breast cancer.